The polycystic ovary syndrome: An example of obesity-related vardiovascular complication affecting young women;La sindrome dell'ovaio policistico: Un esempio di complicanza cardiovascolare correlata all'obesità che colpisce giovani donne

Monaldi Archives for Chest Disease - Cardiac Series

Volumn 66, Issue 1, 2006, Pages 48-53

  Orio, Francesco ^a   Cascella, Teresa ^a   Giallauria, Francesco ^a   Palomba, Stefano ^b   De Lorenzo, Anna ^a   Lucci, Rosa ^a   Ambrosino, Elena ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a   Vigorito, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cardiovascular risk; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

ENDOTHELIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1;

CARDIOPULMONARY FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FEMALE; HEART DISEASE; HEART FUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORTALITY; OBESITY; OVARY POLYCYSTIC DISEASE; REVIEW; RISK FACTOR; WOMEN'S HEALTH;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; RISK ASSESSMENT; RISK FACTORS;

EID: 33751245880     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 33: 853-861.
2. Scarpitta AM, Sinagra D. Polycystic ovary sindrome: an endocrine and metabolic disease. Gynecol Endocrinol 2000; 14: 392-395.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
4. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989-993.
5. Franks S. Are women with polycystic ovary syndrome at increased risk of cardiovascular disease? Too early to be sure, but not too early to act! Am J Med 2001; 111: 665-666.
6. Elting MW, Korsen TJM, Shoemaker J. Obesity rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinemia, dyslipidemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol 2001; 55: 767-776.
7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
8. Legro RS, Kunselman AR, Dunaif a. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607-613.
9. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metabetab 2002; 87: 3871-3875.
10. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002; 77: 1095-1105.
11. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 71: 599-604.
12. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arter Thromb Vascul Biol 1995; 15: 821-826.
13. Conway GS, Agrawal R, Better, Guzi DJ, Jacobs HS. Risk factors for coronary, heart disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37: 119-125.
14. Talbott E, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-2421.
15. Tiras MB, Yalcin R, Noyan V, Maral I, Yildirim M, Dortlemez O, Daya S. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 1999; 14: 1949-1952.
16. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312.
17. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000; 52: 595-600.
18. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103: 1410-1415.
19. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001; 76: 511-516.
20. Kishore J, Harjai MBBS. Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen. Ann Intern Med 1999; 131: 376-386.
21. Dubin D, Pratt RE, Cooke JP, Dzau VJ. Endothelin, a potent vasoconstrictor, is a vascular smooth mitogen. J Vasc Med Biol 1989; 1: 13-16.
22. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metabetab 2001; 86: 4666-4673.
23. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33: 306-310.
24. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metabetab 2001; 86: 66-71.
25. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, Valesini G, De Mattia G, Santucci A. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metabetab 1995; 80: 829-835.
26. Pignoli P, Tyremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406.
27. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metabetab 2004; 89: 4588-4593.
28. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathofisiology of cardiovascular disease. Clin Exp Pharmacol Physiol 1998; 25: 175-184.
29. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
30. Kohler HP, Grant PJ Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
31. Glueck CJ, Rorick MH, Schmerler M, Anthony J, Feibel J, Bashir M, Glueck HI, Stroop D, Wang Y, Tracy TM. Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med 1995; 125: 319-325.
32. Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolityc activity and clotting factors in ischaemic heart disease in women. Br Med J 1996; 312: 1581.
33. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-117.
34. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW. Hyperinsulinemia, hyperglicemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-228.
35. Reaven GM. Syndrome X: 6 years later. Journal of Internal Medicine 1994; 236: 13-22.
36. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-1137.
37. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-494.
38. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-770.
39. Vague P, Juhan-Vague I, Chaberv V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in non diabetic women. Metabolism 1989; 38: 913-915.
40. Shimomura I, Funahashi T, Takahashi K, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contribution to vascular disease in obesity. Nature Medicine 1996; 2: 800-803.
41. Loskutoff DJ, Samad F. 1998 The adipocyte and hemostatic balance in obesity:studies of PAI-1. Arterioscler Thromb Vasc Biol 1996; 18: 1-6.
42. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology 1996; 45: 623-629.
43. Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, Rumley A, Lowe GD, Sattar N. A specific elevation in tissue plasminogen antigen in women with polycystic ovary syndrome. J Clin Endocrinol Metabetab 2002; 87: 3287-3290.
44. Orio F, Palomba S, Cascella T, Tauchmanovà L, Nardo L, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, Zullo F, Colao A, Lombardi G. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary sindrome? Reproductive Biomedicine Online 2004; 9: 505-510.
45. Levy D, Garrison RH, Savage DD, Kannell WB, Castelli WP. Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J Med 1991; 322: 1561-1566.
46. Vetta F, Cicconetti P, Ronzoni S, Rizzo V, Palleschi L, Canarile G, Lupattelli MR, Migliori M, Morelli S, Marigliano V. Hyperinsulinaemia, regional adipose tissue distribution and left ventricular mass in normotensive, elderly, obese subjects. Eur Heart J 1998; 19: 326-331.
47. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-141.
48. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
49. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metabetab 1985; 61: 946-951.
50. Kaushal R, Parchure N, Bano G, Kaski JC, Nussey SS. Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries. Clin Endocrinol (Oxf) 2004; 60: 322-328.
51. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanovà L, Zullo F, Lombardi G, Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metabetab 2004; 89: 3696-3701.
52. Zimmermann S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, Gorlin R, Krakoff LR. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance J Clin Endocrinol Metabetab 1992; 75: 508-513.
53. Ferri C, Desideri G, Baldoncini R, Bellini C, De Angelis C, Mazzocchi C, Santucci A. Early activation of vascular endothelium in non-obese, non-diabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 1998; 47: 660-667.
54. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Artherioscler Thromb Vasc Biol 2003; 23: 168-175.
55. Postiglione A, Rubba P, De Simone B, Patti L, Cicerano U, Mancini M. Carotid atherosclerosis in familial hypercholesterolemia. Stroke 1985; 16: 658-661.
56. Dubuisson JT, Wagenknecht LE, D'Agostino RB Jr, Haffner SM, Rewers M, Saad MF, Laws A, Herrington DM. Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes. Diabetes Care 1998; 21: 1790-179.
57. De Michele M, Panico S, Iannuzzi A, cementano E, Ciardullo AV, Galasso R, Sacchetti L, Zarrilli F, Bond MG, Rubba P. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke 2002; 33: 2923-2928.
58. Rajala U, Laakso M, Paivansalo M, Pelkonen O, Suramo I, Keinane, Kiukaanniemi S. Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metabetab 2002; 87: 5092-5097.
59. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H, Szklo M. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 2002; 155: 437-445.
60. Lakhani K, Seifalian AM, Hardiman P. Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation 2002; 106: 81-85.
61. Mather KJ, Verma S, Corenblum B, Anderson T. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metabetab 2000; 85: 1851-1856.
62. Kelly CJG, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JMC. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metabetab 2002; 87: 742-746.
63. Boirie Y, Short KR, Ahlman B, Charlton M, Nair KS Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin. Diabetes 2001; 50: 2652-2658.
64. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636-1642.
65. De Fronzo R, Ferranini E. Insulin resistance: a multifaceted responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
66. Lakhani K, Prelevic GM, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol 2004; 24: 613-621.
67. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A, Michalis LK. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metabetab 2005; 90: 5088-5095.
68. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346: 793-801.
69. Fleg JL, Pina IL, Balady GJ, Chaitman BR, Fletcher B, Lavie C, Limacher MC, Stein RA, Williams M, Bazzarre T. Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 2000; 102: 1591-1597.
70. Rodnick KJ, Haskell WL, Swislocki AL, Foley JE, Reaven GM. Improved insulin action in muscle, liver, and adipose tissue in physically trained human subjects. Am J Physiol 1987; 253: E489-E495.
71. Rosenthal M, Haskell WL, Solomon R, Widstrom A, Reaven GM. Demonstration of a relationship between level of physical training and insulin stimulated glucose utilization in normal humans. Diabetes 1983; 32: 408-411.
72. Clausen JO, Borch-Johnsen K, Ibsen H, Bergman RN, Hougaard P, Winther K, Pedersen O. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J Clin Invest 1996; 98: 1195-1209.
73. Orio F Jr, Giallauria F, Palomba S, Cascella T, Manguso F, Vuolo L, Russo T, Lombardi G, Colao A, Vigorito C. Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metabetab 2006, in press.